Cyteir Therapeutics (CYT) Stock Forecast, Price Target & Predictions
CYT Stock Forecast
Cyteir Therapeutics stock forecast is as follows: an average price target of $2.00 (represents a -33.55% downside from CYT’s last price of $3.01) and a rating consensus of 'Sell', based on 1 wall street analysts offering a 1-year stock forecast.
CYT Price Target
The average price target for Cyteir Therapeutics (CYT) is $2.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $2.00 to $2.00. This represents a potential -33.55% downside from CYT's last price of $3.01.
CYT Analyst Ratings
According to 1 Wall Street analysts, Cyteir Therapeutics's rating consensus is 'Sell'. The analyst rating breakdown for CYT stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 0 'Hold' (0.00%), 1 'Sell' (100.00%), and 0 'Strong Sell' (0.00%).
Cyteir Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Feb 03, 2023 | - | Morgan Stanley | $2.00 | $1.62 | 23.46% | -33.55% |
The latest Cyteir Therapeutics stock forecast, released on Feb 03, 2023 by Morgan Stanley company, set a price target of $2.00, which represents a 23.46% increase from the stock price at the time of the forecast ($1.62), and a -33.55% decrease from CYT last price ($3.01).
Cyteir Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $3.01 | $3.01 | $3.01 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Cyteir Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Cyteir Therapeutics's last price of $3.01. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Feb 03, 2023 | Morgan Stanley | - | Underweight | Downgrade |
Cyteir Therapeutics's last stock rating was published by Morgan Stanley on Feb 03, 2023. The company Downgrade its CYT rating from "null" to "Underweight".
Cyteir Therapeutics Financial Forecast
Cyteir Therapeutics Revenue Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - |
| High Forecast | - | - | - | - | - |
| Low Forecast | - | - | - | - | - |
| # Analysts | - | - | - | - | 1 |
| Surprise % | - | - | - | - | - |
Cyteir Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. CYT's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Cyteir Therapeutics EBITDA Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 |
| EBITDA | - | - | - | - | $-5.17M |
| Avg Forecast | - | - | - | - | - |
| High Forecast | - | - | - | - | - |
| Low Forecast | - | - | - | - | - |
| Surprise % | - | - | - | - | - |
undefined analysts predict CYT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Cyteir Therapeutics's previous annual EBITDA (undefined) of $NaN.
Cyteir Therapeutics Net Income Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 |
| Net Income | - | - | - | - | $-3.53M |
| Avg Forecast | $55.54M | $48.37M | $56.80M | $-7.21M | $-9.01M |
| High Forecast | $55.54M | $48.37M | $56.80M | $-7.21M | $-9.01M |
| Low Forecast | $55.54M | $48.37M | $56.80M | $-7.21M | $-9.01M |
| Surprise % | - | - | - | - | 0.39% |
Cyteir Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CYT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Cyteir Therapeutics SG&A Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 |
| SG&A | - | - | - | - | $2.50M |
| Avg Forecast | - | - | - | - | - |
| High Forecast | - | - | - | - | - |
| Low Forecast | - | - | - | - | - |
| Surprise % | - | - | - | - | - |
Cyteir Therapeutics's average Quarter SG&A projection for Dec 23 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to CYT last annual SG&A of $2.50M (Sep 23).
Cyteir Therapeutics EPS Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 |
| EPS | - | - | - | - | $-0.10 |
| Avg Forecast | $1.54 | $1.34 | $1.58 | $-0.20 | $-0.25 |
| High Forecast | $1.54 | $1.34 | $1.58 | $-0.20 | $-0.25 |
| Low Forecast | $1.54 | $1.34 | $1.58 | $-0.20 | $-0.25 |
| Surprise % | - | - | - | - | 0.39% |
According to undefined Wall Street analysts, Cyteir Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CYT previous annual EPS of $NaN (undefined).
Cyteir Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| LYEL | Lyell Immunopharma | $1.23 | $9.50 | 672.36% | Hold |
| MOLN | Molecular Partners | $5.22 | $29.00 | 455.56% | Buy |
| NKTX | Nkarta | $5.71 | $21.60 | 278.28% | Buy |
| ANEB | Anebulo Pharmaceuticals | $2.08 | $6.00 | 188.46% | Buy |
| SANA | Sana Bio | $4.47 | $12.00 | 168.46% | Buy |
| RZLT | Rezolute | $5.25 | $13.00 | 147.62% | Buy |
| NUVB | Nuvation Bio | $3.05 | $7.00 | 129.51% | Buy |
| PRLD | Prelude Therapeutics | $2.77 | $6.25 | 125.63% | Sell |
| FHTX | Foghorn Therapeutics | $9.72 | $18.00 | 85.19% | Buy |
| CCCC | C4 Therapeutics | $6.44 | $11.33 | 75.93% | Hold |
| ELYM | Eliem Therapeutics | $8.46 | $13.00 | 53.66% | Buy |
| GRPH | LENZ Therapeutics | $3.18 | $4.00 | 25.79% | Hold |
| CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |
CYT Forecast FAQ
Is Cyteir Therapeutics a good buy?
No, according to 1 Wall Street analysts, Cyteir Therapeutics (CYT) is considered a 'Sell'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of CYT's total ratings.
What is CYT's price target?
Cyteir Therapeutics (CYT) average price target is $2 with a range of $2 to $2, implying a -33.55% from its last price of $3.01. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Cyteir Therapeutics stock go up soon?
According to Wall Street analysts' prediction for CYT stock, the company can go down by -33.55% (from the last price of $3.01 to the average price target of $2), down by -33.55% based on the highest stock price target, and down by -33.55% based on the lowest stock price target.
Can Cyteir Therapeutics stock reach $5?
CYT's average twelve months analyst stock price target of $2 does not support the claim that Cyteir Therapeutics can reach $5 in the near future.
What are Cyteir Therapeutics's analysts' financial forecasts?
CYT's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-16.214M (high $-16.214M, low $-16.214M), average SG&A $0 (high $0, low $0), and average EPS is $-0.45 (high $-0.45, low $-0.45).